Eligibility and antithrombotic use in patients with atrial fibrillation stratified according to risk
| Age (years) | n | Contraindications | Warfarin | Aspirin | No treatment | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Major | Minor | ||||||||||
| Low risk (annual rate 1%) | |||||||||||
| < 65 | 47 | 1 | 8 (17%) | 13/47 (27%) | 5 | 29/47 (62%) | |||||
| Total | 47 | 1 | 8 (17%) | 13/47 (27%) | 5 | 29/47 (62%) | |||||
| Moderate risk (annual rate 4%) | |||||||||||
| < 65 | 11 | 1 | 1 | 5/10 (50%) | 2 | 4/11 (36%) | |||||
| 65–74 | 126 | 9 | 23 | 43/116 (37%) | 49 | 34/126 (27%) | |||||
| > 75 | 76 | 16 | 17 | 2/60 (3%) | 11 | 63/76 (83%) | |||||
| Total | 213 | 26 (12%) | 41 (19%) | 50/186 (27%) | 62 | 101/213 (47%) | |||||
| High risk (annual risk 12%) | |||||||||||
| < 65 | 5 | 0 | 1 | 4/5 (80%) | 1 | 0 | |||||
| 65–74 | 45 | 5 | 8 | 27/40 (67%) | 11 | 7/45 (16%) | |||||
| > 75 | 34 | 7 | 8 | 5/27 (19%) | 13 | 16/34 (47%) | |||||
| Total | 84 | 12 (14%) | 17 (20%) | 36/72 (50%) | 25 | 23/84 (27%) | |||||
Patients receiving warfarin represented as a percentage of patients with no contraindications and eligible for warfarin use.